---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-050957"
form_type: "8-K"
ticker: "CCEL"
cik: "0000862692"
company_name: "CRYO CELL INTERNATIONAL INC"
filed_at: "2021-10-15T23:59:59+00:00"
generated_at: "2026-06-28T20:43:39.996457+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Cryo-Cell Q3 2021 revenue down 8% to $7.5M; net income $857K

## Summary
- Revenue $7.5M vs $8.1M YoY; processing/storage fees $7.3M, public banking $159K.
- Net income $857K ($0.10 per share) vs $784K ($0.10) in Q3 2020.
- Cost of sales +4%, SG&A +3% due to $167K for Cellular Therapies Institute and $131K Duke patent license expenses.
- Recorded $325K decrease in fair value of contingent consideration liability for Cord:Use earn-out.
- No guidance provided; company highlights transformation into cellular therapy company.

## SEC filing metadata
- accession: 0001564590-21-050957
- form_type: 8-K
- ticker: CCEL
- cik: 0000862692
- company_name: CRYO CELL INTERNATIONAL INC
- filed_at: 2021-10-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/862692/000156459021050957/0001564590-21-050957-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/862692/000156459021050957/ccel-8k_20211015.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-050957
- JSON: https://secwatch.observer/filing/0001564590-21-050957.json
- Plain text: https://secwatch.observer/filing/0001564590-21-050957.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.